Release Date: August 29, 2025
CME Track Expiration Date: August 29, 2026
Pharmacist Track Expiration Date: December 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in treating major depressive disorder (MDD). In this educational program, these experts discuss managing patients with MDD by reviewing patient scenarios, reflecting on how to handle challenging cases, and integrating relevant evidence into real-world patient management.
This educational activity is an archive of the live symposium held on July 11, 2025.
Target Audience
This educational activity is directed toward psychiatrists who treat patients with a range of psychiatric disorders. Psychiatric nurse practitioners, psychiatric nurses, pharmacists, and other health care professionals interested in the treatment of patients with psychiatric disorders are invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify best practices for the evaluation, diagnosis, and monitoring of psychiatric disorders and associated comorbid conditions
- Evaluate newer and emerging data regarding approved and investigational agents
- Implement evidence-based treatment plans
Jason Kellogg, MD
CEO of Progeny Psychiatric Group
Huntington Beach, CA
Disclosures: Speaker’s Bureau: Acadia Pharmaceuticals, Neurocrine, Otsuka, Teva.
Gus Alva, MD, DFAPA
Pacific Neuropsychiatric Specialists
Medical Director, ATP Clinical Research
Assistant Professor
Department of Psychiatry and Neuroscience
University of California, Riverside
Riverside, CA
Disclosures: Grant/Research Support: AbbVie, Accera, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Sage, Suven, TransTech; Consultant: AbbVie, Accera, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Neurotrope, Genentech, Intra- Cellular, Janssen, Lundbeck, Neurim, Novartis, Otsuka, Roche, Sage, Suven, TransTech; Speaker’s Bureau: AbbVie, Accera, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Sage, Suven, TransTech.
Melanie Barrett, MD
Psychiatrist
LifeStance Health
Edmond, OK
Melanie Barrett, MD, has no relevant financial relationships with ineligible companies.
Yvette Elpidio, MSN, FNP-C
Family Nurse Practitioner
Pacific Neuropsychiatric Specialists
Costa Mesa, CA
Yvette Elpidio, MSN, FNP-C, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.